Advertisement

Journal of Nuclear Cardiology

, Volume 23, Issue 4, pp 840–842 | Cite as

Rubidium-82 uptake in metastases from neuroendocrine tumors: No flow response to adenosine

  • Philip Hasbak
  • Lotte Hahn Enevoldsen
  • Marie Øbro Fosbøl
  • Dorthe Skovgaard
  • Ulrich Peter Knigge
  • Andreas Kjær
Images that Teach

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms of neuroendocrine origin. The majority of gastro-entero-pancreatic and bronchopulmonary NETs overexpresses somatostatin receptors. Ga-68-DOTA(0)-Phe(1)-Tyr(3)-octreotide (Ga-68-DOTATOC) is a Ga-68-labeled somatostatin receptor analog. Ga-68-DOTATOC PET/CT combines somatostatin receptor imaging with a computed tomography (CT) scan and is used for diagnosing, staging, and restaging of NETs. Arterial hyperperfusion using contrast-enhanced CT and ultrasound have previously been reported to characterize both metastasis from NETs and primary NETs.

We demonstrate Rb-82 (Rb) uptake in metastases from NETs in two patients undergoing Ga-68-DOTATOC PET/CT and Rb-PET/CT as part of a research protocol (Figures 13). Rb-PET is mainly used for myocardial perfusion studies for the evaluation of patients with coronary artery disease. But Rb uptake has also been demonstrated in different malignant processes (brain, breast cancer, lung...

Keywords

Multiple Myeloma Octreotide Neuroendocrine Tumor Myocardial Blood Flow Myocardial Flow Reserve 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Mirpour S, Khandani AH. Extracardiac abnormalities on rubidium-82 cardiac positron emission tomography/computed tomography. Nucl Med Commun 2011;32:260-4.CrossRefPubMedGoogle Scholar
  2. 2.
    Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007;34:1765-74.CrossRefPubMedGoogle Scholar
  3. 3.
    Kalhan A, Gharibi B, Vazquez M, Jasani B, Neal J, Kidd M, et al. Adenosine A2A and A2B receptor expression in neuroendocrine tumours: Potential targets for therapy. Purinergic Signal 2012;8:265-74.CrossRefPubMedGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2015

Authors and Affiliations

  • Philip Hasbak
    • 1
  • Lotte Hahn Enevoldsen
    • 1
  • Marie Øbro Fosbøl
    • 1
  • Dorthe Skovgaard
    • 1
  • Ulrich Peter Knigge
    • 2
    • 3
    • 4
  • Andreas Kjær
    • 1
    • 4
  1. 1.Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular ImagingUniversity of CopenhagenCopenhagenDenmark
  2. 2.Department of Surgery CRigshospitalet, University of CopenhagenCopenhagenDenmark
  3. 3.Department of Endocrinology PERigshospitalet, University of CopenhagenCopenhagenDenmark
  4. 4.European NET Centre of ExcellenceRigshospitalet, University of CopenhagenCopenhagenDenmark

Personalised recommendations